The U.S. Food and Drug Administration has cleared an Investigational New Drug application from Anixa Biosciences Inc. (Nasdaq: ANIX) for its breast cancer vaccine, which was invented by a Cleveland Clinic research term.
This breast cancer vaccine technology was invented and developed by Cleveland Clinic immunologist Dr. Vincent Tuohy, and his research team developed the technology. Dr. Thomas Budd, a Clinic oncologist, will lead the clinical trial, according to a news release.
Click here to read the complete story.
Story excerpt provided by Crain’s Cleveland Business.
Written by Lydia Coutré.
Originally published December 21, 2020.